Dihexa vs ARA-290
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
A potent cognitive-enhancing peptide derived from angiotensin IV. Reported to be 10 million times more potent than BDNF at promoting synaptogenesis.
Also: Cibinetide, ARA 290
An 11-amino acid peptide derived from erythropoietin (EPO) that activates the innate repair receptor. Unlike EPO, it has no erythropoietic activity but provides cytoprotective, anti-inflammatory, and tissue-protective effects.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- ARA-290 has stronger research evidence (Phase II/III Trials) compared to Dihexa (Animal Studies).
Detailed Comparison
| Attribute | Dihexa | ARA-290 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Dihexa activates hepatocyte growth factor (HGF) signaling through the c-Met receptor. This promotes dendritic spine formation, enhances synaptic connections, and supports neuronal survival. Crosses blood-brain barrier orally. | ARA-290 selectively activates the innate repair receptor (IRR), a heterodimer of EPOR and CD131 (β common receptor). This receptor is expressed on damaged and inflamed tissues. Activation triggers anti-apoptotic, anti-inflammatory, and tissue-protective pathways without stimulating red blood cell production. |
| Common Dosing | 5-20 mg oral or sublingual daily Once daily, effects can last up to 10 days | 4 mg daily Once daily |
| Administration | Oral, sublingual, or intranasal | Subcutaneous injection |
| Typical Duration | Cycles of 2-4 weeks | 28-day courses in trials |
| Best Time to Take | Morning | Consistent daily timing |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Animal studies show remarkable cognitive enhancement and reversal of scopolamine-induced memory deficits. Research demonstrates increased dendritic spine density. Limited human data but significant interest in nootropic community. | Phase II/III clinical trials for diabetic neuropathy show improvement in corneal nerve fiber density and small fiber function. Orphan Drug Designation granted in both US and EU for sarcoidosis treatment. Studies demonstrate efficacy in small fiber neuropathy, neuropathic pain, and sarcoidosis-related symptoms. Being developed by Araim Pharmaceuticals. |
Frequently Asked Questions: Dihexa vs ARA-290
What is the difference between Dihexa and ARA-290?
Dihexa is a cognitive peptide that a potent cognitive-enhancing peptide derived from angiotensin iv. reported to be 10 million times more potent than bdnf at promoting synaptogenesis. ARA-290 is a cognitive peptide that an 11-amino acid peptide derived from erythropoietin (epo) that activates the innate repair receptor. unlike epo, it has no erythropoietic activity but provides cytoprotective, anti-inflammatory, and tissue-protective effects. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Dihexa or ARA-290?
Neither is universally "better" - the choice depends on your specific goals. Dihexa is typically used for cognitive purposes, while ARA-290 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Dihexa and ARA-290 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Dihexa and ARA-290 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Dihexa and ARA-290 is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.